EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
2012; Springer Science+Business Media; Volume: 461; Issue: 3 Linguagem: Inglês
10.1007/s00428-012-1281-4
ISSN1432-2307
AutoresErik Thunnissen, Lukas Bubendorf, Manfred Dietel, Göran Elmberger, Keith M. Kerr, Fernando López-Rı́os, Holger Moch, Włodzimierz Olszewski, Patrick Pauwels, Frédérique Penault‐Llorca, Giulio Rossi,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoIn non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.
Referência(s)